Activen Sa

Activen SA is a company focused on developing and commercializing innovative active ingredients for the dermo-cosmetic industry, utilizing miniproteins™ to enhance skin treatments. Founded in 2010 and headquartered in Lausanne, Switzerland, Activen SA specializes in creating active ingredients for the dermo-cosmetic sector. The company was acquired by Remora Capital on July 27, 2015, and has engaged in one major deal since its inception. Jean-Marc Le Doussal is the founder.

Notably, Activen has not undergone major pivots or changes in its business strategy. Activen SA specializes in the development and commercialization of innovative active ingredients for the dermo-cosmetic industry, with a focus on miniproteins™. These naturally occurring proteins are engineered to penetrate the skin effectively, targeting specific receptors to enhance efficacy in applications like anti-aging, skin regeneration, and non-invasive aesthetics. With a proprietary database of over 100,000 miniproteins™, Activen aims to unlock new applications in skin health and beauty, addressing conditions such as atopic dermatitis and psoriasis.

Their flagship products, XEP®-018 and XEP®-716 miniproteins™, are designed for quick results in reducing fine lines and wrinkles and for promoting skin regeneration, respectively. Activen's products are marketed to cosmaceutical companies and brands globally, with a strong presence in Europe, Asia, and North America, catering to a diverse clientele that includes dermatologists, cosmetic manufacturers, and research institutions. Activen generates revenue through B2B partnerships with cosmetic companies and dermatological product manufacturers, offering its miniprotein™ active ingredients for incorporation into their formulations. The company participates in transactions involving long-term contracts and supply agreements, ensuring consistent delivery of high-purity actives.

Clients typically purchase these miniproteins™ in bulk quantities, aligning with their production needs, and the transactions include provisions for quality assurance and full traceability of the ingredients. Pricing structures are determined based on the specific formulations and concentrations required by clients, with flagship products like XEP®-018 and XEP®-716 positioned as premium offerings in the market. This model allows Activen to serve a wide range of end users seeking innovative solutions in skin care and aesthetic treatments, establishing a robust revenue stream that supports ongoing research and development initiatives. Activen SA is focused on enhancing its product portfolio and expanding its market presence.

The company has plans to launch new miniproteins™ aimed at addressing additional skin conditions by 2024. Activen is also targeting growth in new markets, specifically in Asia and North America, to increase its global footprint. The recent acquisition by Remora Capital will support these initiatives, particularly in funding product development and marketing efforts to reach a broader clientele.